Business Context and Reporting Period
This Form 8-K filing by CareDx, Inc. (a Delaware corporation) was submitted on November 26, 2018. The report discloses the appointment of a new senior executive officer and related compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation details:
- Base Salary: $400,000 annualized.
- Target Bonus: 70% of base salary.
- Equity Grant: 100,000 stock options and 50,000 restricted stock units (RSUs).
Material Changes
On November 26, 2018, CareDx, Inc. appointed Reginald Seeto, MBBS, as President and Chief Business Officer, effective immediately. Dr. Seeto reports to CEO Dr. Peter Maag. This appointment follows his tenure as Chief Operating Officer at Ardelyx, Inc. and various senior roles at AstraZeneca/MedImmune.
Outlook, Risks, and Unusual Items
Compensatory Arrangements: Dr. Seeto's employment is "at-will." The stock options vest 25% on the first anniversary and monthly thereafter. The RSUs vest 25% annually. The company also executed standard change of control and indemnification agreements.
Related Party Transactions: The filing explicitly states there are no reportable family relationships or related party transactions involving Dr. Seeto.
Management Commentary: The filing references a press release (Exhibit 99.1) announcing the appointment but does not include additional strategic outlook or risk factors within the text provided.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 100,000 stock options granted to Dr. Seeto.
- Review the full text of the Offer Letter (Exhibit 10.1) for termination provisions and severance details.
- Confirm the impact of this executive appointment on the company's strategic direction via the attached press release (Exhibit 99.1).
- Check subsequent filings for any changes to the company's capital structure resulting from the equity grants.